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bstract
CD69 is a very early cell activation antigen expressed on the surface of activated immune cells. It can appear within 1–2 h of activation and
xhibits maximal expression levels between 18 and 24 h after stimulation. In this work, the expression profile of CD69 in mice splenocytes was
valuated following exposure to the biopolymers, chitosan or alginate and the immunostimulatory factors, CpG ODN 1826 or concanavalin A.
e have shown that both polymers are able to upregulate expression of CD69 on B cells and CD4+ T-lymphocytes, with alginate as the least
otent stimulus. Moreover, the expression of the CD69 molecule on CD8+ T-lymphocytes was observed only in splenocytes cultured with chitosan.
owever, activation of lymphocytes did not result in cell proliferation. On the other hand, CpG ODN proved to be a potent B cell stimulator,
s evidenced by the upregulation of CD69, but had less effect on T-cells. These results, together with previous discoveries reported in scientific
iterature, may contribute to the clarification of the adjuvant effect, which has been attributed to chitosan and alginate formulations or to the
iopolymers itself.
2007 Elsevier B.V. All rights reserved.
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. Introduction
The combination of biomaterials with proteins, DNA, vac-
ines, and cells has been a matter of study in several groups.
wo well-known examples are the development of polymeric
arriers of vaccines and tissue engineered constructs in which
ells are delivered with a polymer component for the reno-
ation or replacement of damaged tissue or organ function.
n these two examples, different potential immune responses,
ue to the possible adjuvant effect of the biomaterial would
e required. Clearly, from a tissue engineering point of view,
mmune responses are to be minimized or altogether avoided
hile an adjuvant effect of the polymeric vaccine delivery sys-
em would be desirable and even necessary, particularly for weak
∗ Corresponding author. Tel.: +351 239859927; fax: +351 239827126.
E-mail address: olga@ci.uc.pt (O. Borges).
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oi:10.1016/j.ijpharm.2007.01.021ntigens (Babensee and Paranjpe, 2005). Among the natural
iomaterials, chitosan and alginate have been used for both of
he previously stated purposes. In particularly the use of algi-
ate (Kim et al., 2002; Suckow et al., 2002; Tafaghodi et al.,
006) and chitosan (van der Lubben et al., 2003; Xu et al., 2004;
audner et al., 2005; Read et al., 2005) particles as an antigen
elivery system were used with success in a number of vacci-
ation studies. The mechanism, by which particulates showing
djuvant effect is not completely understood. In general, are
hought that particulate delivery systems promote trapping and
etention of antigens in local lymph nodes and protecting them
rom degradation, which seems to be important in triggering pro-
ective T cell responses (O’Hagan, 2006). However in a recent
tudy (Read et al., 2005), a soluble derivative of the chitosan
as administered in solution with influenza vaccine. An adju-
ant effect of the chitosan was observed; therefore a different
echanism in this case may have to be considered and investi-
ated.
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We also have been particularly interested in the use of chi-
osan and alginate for the design of vaccine carriers. In a
ecent publication (Borges et al., 2005), we described the devel-
pment of a new vaccine delivery system of alginate coated
hitosan nanoparticles, specially designed to deliver vaccines
nto mucosal surfaces. This delivery system is now being used
n mucosal vaccination studies with the recombinant hepatitis
surface antigen associated with the adjuvant, the CpG ODN
826. By this reason, the study of the effect of the polymers,
sed in our group for the preparation of the nanoparticles, on
he cells from the immune system are of extreme importance.
Both polymers are naturally occurring polysaccharides.
hitosan, a copolymer of d-glucosamine and N-acetyl-d-
lucosamine is a derivative of chitin, one of the most abundant
olysaccharides in nature. Alginate is composed of alternating
locks of 1–4 linked -l-guluronic (G) and -d-mannuronic
M) acid residues. The sources of these polymers as well as
heir physical and chemical properties have been extensively
eviewed in several publications (Felt et al., 1998; van der
ubben et al., 2001; George and Abraham, 2006).
The immunostimulatory properties, found in certain algi-
ates, in same cases have been associated with the presence
f impurities, like endotoxins or mitogenic contaminants in
lginate raw materials (Klock et al., 1997; Jork et al., 2000;
rive et al., 2005). In a recent work, the production of the
roinflammatory cytokine TNF-was approximately 100 times
igher in the case of non-biomedical grade alginate in compar-
son to the purified one (Orive et al., 2005). According to the
ame authors, this feature has implications on the utilization
f impure alginates, for instance as carriers for cell immobi-
ization. In fact, TNF- is considered to be a potent cytokine
hat is known to activate leukocytes, stimulate fibroblast pro-
iferation, promote migration of inflammatory cells into the
ntercellular matrix, and trigger local secretion of other proin-
ammatory cytokines. In addition to the considerations above, a
accine nanocarrier should also be made with purified alginates
iven that stimulation of TNF-would lead to an overgrowth of
ollagen-secreting fibroblasts and activated macrophages secret-
ng growth regulatory cytokines over the nanocarrier and may
ave as a consequence, an alteration of the vaccine release from
he nanocarrier (Orive et al., 2005). On other hand, a highly puri-
ed alginate, with low polyphenol and protein content, prepared
rom Laminaria pallida, was evaluated in vitro using mice lym-
hocytes and no evidence of significant mitogenic activity was
bserved (Jork et al., 2000). However there are also some stud-
es that showed that the mannuronic acid rich alginates, have
tself immunostimulating properties, stimulating monocytes to
ytokine production (Otterlei et al., 1993) in where the TLR2
nd TLR4 seemed to be involved (Flo et al., 2002). In a more
ecent study (Babensee and Paranjpe, 2005), the effect of bio-
aterials on dendritic cell maturation was evaluated and it was
emonstrated that the expression levels of CD86, CD40 and
LA-DQ (MHC class II) molecules, indicative of dendriticell maturation, were decreased in the presence of alginate.
n the contrary, the presence of chitosan in the same in vitro
tudy caused a high expression level of the same co-stimulatory
olecules.
n
f
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The expression of CD69 was never investigated in lym-
hocytes cultured with chitosan; however the activation of
ymphocytes following the administration of chitosan has been
eported in some recent publications. For instance, it was shown
hat rats fed orally with a purified low molecular weight chi-
osan triggered the release of IL-10 as well as the expression
f IL-4 and TGF- mRNA at the gut mucosa local microen-
ironment and stimulated CD3+ T-lymphocytes in the spleen
Porporatto et al., 2005). The presence of chitosan also caused
he enhancement of the natural killer (NK) cell activity in intesti-
al intraepithelial lymphocytes and splenic lymphocytes (Maeda
nd Kimura, 2004). Furthermore, it has been demonstrated that
hitosan (Bianco et al., 2000; Mori et al., 2005), and chitosan
icroparticles (Nishimura et al., 1987; Shibata et al., 1997) are
ble to up-regulate, to some extent, a number of macrophage
unctions. For instance, a low molecular weight water solu-
le chitosan induced the activation of macrophages through the
roduction of cytokines such as IFN-, IL-12, and IL-18 from
he intestinal intraepithelial lymphocytes (Maeda and Kimura,
004). Another example found in Scientific literature based on
n vitro studies, shown that chitosan nanoparticles (1–10m)
hat can be phagocytized, stimulated alveolar macrophages, but
t a significantly lower level than that elicited by oxidative
esponses observed with phagocytized chitin (Shibata et al.,
997). In a more recent study (Mori et al., 2005), using peri-
oneal macrophages, different results among the biomaterials
hitosan, low molecular weight chitosan (LMW), and chitin
ere obtained. Therefore, chitosan treatment induced activation
arkers, such as the major histocompatibility complex (MHC)
lass I, class II, Fc receptors, transferrin receptor, mannose
eceptor, Fas, and macrophage inflammatory protein (MIP)-2,
hereas chitin and LMW chitosan induced only the expres-
ion of MHC class I and II molecules. Thus, small variations
n molecular weight or degree of deacetylation on chitosan
olecule might lead to different degrees of activation in cells
rom the immune system (Ueno et al., 2001; Matsunaga et al.,
006).
The adjuvant effects of CpG ODN have been studied inten-
ively in the last few years. Briefly, CpG ODN directly stimulates
mmune cell types that express Toll-like receptor 9 (TLR9), with
uman B cells and plasmocytoid dendritic cells (pDCs) being
he dominant cell types expressing TLR9 (Klinman, 2004). Acti-
ation of these cells promotes the production of T helper 1 (Th1)
nd proinflammatory cytokines and the maturation/activation of
rofessional antigen-presenting cells (APC) (Klinman, 2004).
hese actions enable CpG ODNs to act as immune adju-
ants which can accelerate and boost antigen-specific immune
esponses. The maintenance of close physical contact between
he CpG and the antigen has been reported to be the ideal situa-
ion for achieving optimal results (Davis et al., 1998). This can
e realized by encapsulating the CpG and the antigen together
n the same delivery system. Moreover, if the polymers used
o construct the delivery system, for instance chitosan and algi-
ate, have themselves immune stimulating properties, then the
ormulation, may have optimized adjuvant properties.
Therefore, the main goal of this work was to evaluate the
apacity of each component of our coated nanoparticles, and
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ompare them with the adjuvant, CpG ODN 1826, in order to
etermine which method resulted in the optimal activation of B-
nd T-lymphocytes. With this purpose, the CD69 receptor, which
s considered a very early cell activation antigen, expressed on
he surface of activated immune cells, was examined for the
rst time on splenocytes cultured with the raw materials chi-
osan or alginate, which are used in the preparation of the coated
anoparticles. This cell surface antigen can appear within 1–2 h
f activation and exhibits maximal expression levels between 18
nd 24 h after stimulation, making it a useful tool, albeit one that
as not been fully investigated, for early evaluation of the effect
f biomaterials in the stimulation of immune cells.
. Materials and methods
.1. Materials
.1.1. Animals
In this study, 6–7-week-old male BALB/c mice were used
Harlan Iberica, Barcelona, Spain). Animals were housed and
ared for at the animal resource facilities of the Faculty of Phar-
acy of the University of Porto, in accordance with institutional
uidelines.
.1.2. Polymers
Fine grade pure chitosan was purchased from Primex Bio-
hemicals AS (Avaldsnes, Norway). According to the provider’s
pecifications, the degree of deacetylation is 95% (titration
ethod) and the viscosity is 8 cP (measured in 1% solutions
n 1% acetic acid) that corresponds to a low molecular weight
hitosan. (According to the provider’s specifications a chitosan
ith a molecular of 40 kDa and another with 60 kDa have a
iscosity of 25 and 35 cP, respectively.)
A low molecular weight sodium alginate (MANUCOL LB®)
as kindly donated by ISP Technologies Inc. (Surrey, UK).
ccording to the provider’s specifications, the typical values
or the percentage of mannuronic and guluronic acid for Manu-
ol LB is 61 and 39%, respectively, and an estimated molecular
eight of 18 kDa.
Both polymers meet the requisites described in the European
harmacopoeia for use in pharmaceutical formulations. In this
ork a 22m filtered solutions of the polymers were used.
.1.3. Reagents
Class B, CpG ODN 1826 (5′-TCC ATG ACG TTC
TG ACG TT-3′) was purchased from Coley Pharmaceuti-
al Group (Ottawa, Canada), concanavalin A (Con A) was
urchased from Sigma Chemicals (St. Louis, USA), certified
etal bovine serum (FBS) and l-glutamine (200 mM) were pur-
hased from Gibco (Invitrogen Co., Paisley, Scotland, UK),
M HEPES buffer (0.85% NaCl), RPMI 1640 medium without
-glutamine and Pen-Strep (10,000 U penicillin/ml; 10,000g
treptomycin/ml) were purchased from Biowhitaker (Cam-
rex Bio Science, Verviers, Belgium). [Methyl-3H]thymidine
1.0 mCi/ml) was obtained from Amersham Biosciences (UK),
-Phycoerythrin (PE)-conjugated hamster anti-mouse CD69,
uorescein isothiocyanate (FITC)-conjugated rat anti-mouse
t
o
(
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D4 and FITC-conjugated rat anti-mouse CD8 were obtained
rom BD Biosciences (Madrid, Spain). The FITC-conjugated
oat anti-mouse IgM (anti-) was purchased from PharMin-
en (San Diego, CA, USA). All others reagents used were
f analytical grade. All solutions were prepared in Millipore
ater.
.2. Methods
.2.1. Preparation of spleen cell suspensions
Three mice were euthanized by cervical dislocation and their
pleens were aseptically removed. Individual spleen cell sus-
ensions were prepared in a Petri dish using curved needles
nd washed twice with RPMI 1640. The final suspension was
djusted to a final concentration of 1 × 107 cells/ml in complete
PMI 1640 medium (supplemented with 10% (v/v) fetal bovine
erum, 1% (v/v) glutamine, 1% (v/v) Pen-Strep and 2% (v/v) 1 M
EPES buffer).
.2.2. Polymer solutions
The 0.25% (w/v), 0.125% (v/v), and 0.01% (v/v) chitosan
olutions were prepared in complete RPMI medium acidified
ith acetic acid. Sodium alginate was first dissolved in HEPES
uffer (0.5%, w/v) and then diluted in complete RPMI (0.25%,
/v), 0.125% (v/v), and 0.01% (v/v)). Immediately following,
he polymer solutions were aseptically filtered and incubated
ith the cells. The solvents used for the preparation of the poly-
er solutions (RPMI acidified with acetic acid and HEPES)
ere also used as controls for the experiment.
.2.3. Cell culture in the presence of the polymers and
itogens
Using sterile 96-well flat-bottomed tissue culture plates,
5l of splenocyte suspension (1 × 107 cells/ml) from three
ndividual mice were plated in triplicate along with 25l of
omplete RPMI solution with the mitogen [Con A (50g/ml)
r CpG ODN (50g/ml) or without mitogen (control)] and 25l
f a complete RPMI solution of the polymer [chitosan; or sodium
lginate; or without polymer (control)]. Finally the volume of
he well was diluted to 200l with complete RPMI and incu-
ated at 37 ◦C with 95% relative humidity and in the presence
f 5% CO2.
.2.4. Immunofluorescence labelling
After 20 h of incubation, cells were washed and resuspended
n cold phosphate buffered saline (PBS) supplemented with
% FBS, resulting in a concentration of 0.5 × 106 cells/well.
he cells were then incubated in the dark for 30 min at 4 ◦C
ith saturating concentrations of PE-conjugated hamster anti-
ouse CD69 and FITC-conjugated rat anti-mouse CD4 or
ITC-conjugated rat anti-mouse CD8 or FITC-conjugated goat
nti-mouse IGM (anti-). After incubation, cells were washed
hree times with PBS-FBS and then resuspended with 500l
f PBS-FBS. To exclude dead cells, 2.5l propidium iodide
50l/ml) was added just before data acquisition. At least 10,000
vents were analysed by flow cytometric acquisition, performed
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n a fluorescent activated cell sorter (FACS Calibur) (BD Bio-
ciences, Madrid, Spain). Data were analysed by CellQuest
oftware (BD Biosciences, Madrid, Spain). Viable lymphocytes
ere selected on the basis of FSC/SSC values.
The concentration of the polymers studied was kept at
.156 mg/ml. Data were presented as the mean ± S.E.M. for
hree experiments and statistical significance was assessed using
epeated measured one-way ANOVA followed by Dunnett’s
ost-test using the GraphPad Prism 4 software. Differences were
onsidered significant when p < 0.05..2.5. Lymphocytes proliferation assay
Splenocytes were obtained and cultured in a flat-bottomed
6-well plate with and without the mitogens and polymers as
escribed above. The cells were cultured for 96 h at 37 ◦C and
w
w
a
r
ig. 1. Forward scatter counts-histograms (FSC-H) of B and T lymphocytes (CD4+ a
DN for 20 h. The filled histograms represent the group control (splenocytes withou
esults are representative of two separate experiments using three animals per experimPharmaceutics 337 (2007) 254–264 257
n the last 8 h of incubation, each well was pulsed with 1Ci of
methyl-3H] thymidine. 96 well plates with the cells were frozen
or further analysis. The cells were later thawed and harvested
nto a Fiberglass filter (filter mats, molecular devices, Skatron,
ier, Norway) using a semiautomatic cell harvester (Scatron
nstruments, USA) and thymidine incorporation was counted by
tandard liquid scintillation techniques with a Beckman LS 6500
cintillation counter (Beckman Coulter Inc., Fullerton, USA).
hymidine incorporation was expressed as counts per minute
cpm).
The concentration in the well of the polymers studiedere: conc1 = 0.312 mg/ml and conc2 = 0.0125 mg/ml. Data
ere presented as a mean ± S.E.M. for the three experiments
nd statistical significance was assessed using a nonparamet-
ic ANOVA with Kruskal–Wallis analysis using the GraphPad
nd CD8+) from Balb/c mice spleen stimulated with alginate or chitosan or CpG
t stimulation) and the open histograms the stimulated (treatment) group. The
ent and each treatment.
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rism 4 software. Differences were considered significant when
< 0.05.
. Results
.1. Effect of alginate or chitosan polymers or the
mmunostimulant CpG ODN on the size and granularity of
pleen mouse lymphocytes
The spleen is a lymphoid organ combining the innate and
daptive immune system in a unique and organized way (Mebius
nd Kraal, 2005). The principal reason for the choice of spleen
ells in this study was related to the fact that they are obtained and
ultured easily and that they are a very sensitive representative of
ifferent lymphocytes. According to FACS analysis performed
n our own laboratory, a primary culture of mixed spleen cells
m
t
w
c
ig. 2. Side light scatter counts-histograms (SSC-H) of B and T lymphocytes (CD4
pG ODN for 20 h. The filled histograms represent the group control (splenocytes w
he results are representative of two separate experiments using three animals per exPharmaceutics 337 (2007) 254–264
ormally contain more than 50% of B lymphocytes, more than
0% of T lymphocytes (20% CD4+; 12% CD8+) and of the
emaining cells, less than 10% were erythrocytes, fibroblasts,
acrophages, dendritic cells, and granulocytes.
Lymphocytic morphological alterations, as a consequence of
he engorgement of the rough endoplasmic reticulum, which
ormally accompany cell activation, can be observed by flow
ytometry analysis, combining forward light scatter (FSC) and
ide light scatter (SSC). In general, activated cells exhibited a
ramatic increase in both forward and side scatter.
As a positive control, cells from the mouse spleen were cul-
ured with concanavalin A (Con A), a classical lymphocyteitogen. As was expected and shown in Fig. 1, an increase of
he forward scatter counts (FSC) of the stimulated lymphocytes
as observed, suggesting augmentation of cell size. The size
hange was accompanied by an increase in cellular granularity
+ and CD8+) from Balb/c mice spleen stimulated with alginate or chitosan or
ithout stimulation) and the open histograms the stimulated (treatment) group.
periment and each treatment.
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SSC) in all lymphocyte subtypes (CD4+, CD8+, and B cells)
fter 20 h culture (Fig. 2). In contrast, the presence of CpG ODN
n the splenocytes culture, subjected to the same conditions did
ot induce a size (Fig. 1) and granularity (Fig. 2) augmenta-
ion in CD4+ and CD8+ T-cells, however, a remarkable increase
f these two parameters was observed in B cells. These results
upport the hypothesis that CpG ODN is predominately a B
ymphocyte activator.
In the same way, to assess the differential effect of the alginate
nd chitosan biopolymer contact on spleen cell morphology,
he cells were cultured with the polymers for 20 h. Preliminary
esults (Borges et al., 2006) have shown cell viability near 100%
ith splenocytes cultured with 0.21 mg/ml of the polymers for
5 h. In order to obtain non-toxic concentrations of polymers,
e decided to decrease the concentration of polymers in the cell
ulture to 0.156 mg/ml because we increased the incubation time
o 20 h.
As shown in Figs. 1 and 2, both polymers caused an increase
n FSC and SSC of B cells. Chitosan was the polymer that
howed a stronger effect, particularly on cell granularity (SSC).
oreover, CD4+ and CD8+ T-lymphocytes treated with chi-
osan also showed a strong modification of their morphology
SSC and FSC). T-lymphocytes treated with alginate did not
how morphological differences (SSC and FSC) when com-
ared to the appropriate control (filled overlap histogram in
igs. 1 and 2).
o
w
n
ig. 3. Effect of the different compounds on the expression of the CD69 receptor on CD
nd Con A and the biopolymers chitosan and alginate. A combination between the b
epresent the group control (untreated) and the open histograms the stimulated (pretr
hree animals per experiment and each treatment. The right picture corresponds to
econd experiment. The values are mean ± S.E.M. of the percentage of the positive
p < 0.01.Pharmaceutics 337 (2007) 254–264 259
.2. Evaluation of the expression of CD69 by T and B
ouse spleen lymphocytes
As a positive control, we used Con A to induce the expres-
ion of CD69 in B and T lymphocytes and the results are shown
n Figs. 3–5. The CD69 expression results in spleen lympho-
ytes exposed to equal concentrations of polymers, alginate or
hitosan (0.156 mg/ml), or CpG ODN (6g/ml) are also shown
n Figs. 3–5. The percentage of CD4+ T-lymphocytes that nat-
rally express CD69 is very low (3%). The addition of alginate
o cell cultures result in a four-fold increase (13%) of CD69+
-lymphocytes (Fig. 3). A similar result (18%) was obtained
ith CpG ODN 1826, which correlates well with the above
esults of size and granularity. In contrast, CD4+ T-lymphocytes
esponded with elevated CD69 expression levels to the presence
f chitosan (90%), similar to those observed with the positive
ontrol (Con A). The same robust effect of chitosan was also
bserved in CD8+ T lymphocytes (85%) (Fig. 4), contrasting
ith alginate, which has been shown not to induce CD69 expres-
ion on CD8+ cells. Therefore, these results are again, more
losely related to the granularity and size results shown above.
ollowing CpG ODN 1826 stimulation, we observed about 50%
f CD8+ T-lymphocytes that upregulated CD69; however there
as considerable variation in expression (Fig. 4).
The effect of CpG ODN or the polymers chitosan or algi-
ate on B lymphocyte CD69 activation was also studied. The
4+ splenocytes. The compounds used were the immunostimulators, CpG ODN
iopolymers and the immunostimulators were also used. The filled histograms
eated) group. The results are representative of two separate experiments using
the entire data of one experiment. Similar histograms were obtained with the
CD4 cells that express the CD69 antigen, obtained from three different mice.
260 O. Borges et al. / International Journal of Pharmaceutics 337 (2007) 254–264
Fig. 4. Effect of the different compounds on the expression of the CD69 receptor on CD8+ splenocytes. The compounds experienced were the immunostimulators,
CpG ODN and Con A and the biopolymers chitosan and alginate. A combination of the biopolymers and the immunostimulators were also used. The filled histograms
represent the group control (untreated) and the open histograms the stimulated (pretreated) group. The results are representative of two separate experiments using
three animals per experiment and each treatment. The right picture corresponds to the entire data of one experiment and similar histograms were obtained with
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ice.*p < 0.05; **p < 0.01.
esults presented in Fig. 5 show a strong effect of all the assayed
iopolymers, with alginate showing the smallest effect (about
0%) and chitosan the strongest effect (85%). More than 95%
f the B cells expressed the CD69 antigen when cultured with
pG ODN, which is in close agreement with a recent published
tudy (Wang and Krieg, 2003). This study was done with two
ets of ODN with similar base compositions and it was demon-
trated that ODN 1826 is a strong stimulator driving B cells to
xpress CD69 in a dose-dependent fashion. Considering that our
esults were obtained with lower concentrations of the ODN’s
nd shorter culture times, these results may reflect saturation of
he CD69 expression on B cells.
To examine possible synergistic effects using a combination
f the polymers chitosan or alginate and the immunostimulator,
pG ODN 1826, the cells were incubated in the presence of both,
pG and polymers (chitosan or alginate). Chitosan, surprisingly,
howed to be a strong CD69 expression inducer for both B and
-lymphocytes, such that CD69 expression could not further be
pregulated by CpG. However, a statistically significant differ-
nce was observed for the CD8+ T-lymphocyte subpopulation
ncubated only with chitosan or only with the positive control,
on A. With respect to alginate (Figs. 3 and 4), the results clearlyhowed that a synergy with CpG does not occur in T-lymphocyte
opulations. Furthermore, the presence of alginate in the lym-
hocyte culture together with CpG dowregulated the expression
f CD69 antigen on CD8+ lymphocytes (Fig. 4) when compared
r
n
aitive CD8 cells that express the CD69 antigen, obtained from three different
o the cells incubated only with CpG. Potentially, as a result of
he saturation of B-lymphocyte CD69 expression induced by
pG, the additional presence of alginate in cell culture did not
roduce any statistically significant results (Fig. 5).
.3. Study of the effect of chitosan and alginate polymers
n lymphocyte proliferation
To study whether the polymers, chitosan or alginate, or
he CpG ODN have a proliferative effect on lymphocytes and
hether CpG activates the lymphocytes in synergy with the poly-
ers, mouse spleen lymphocytes were cultured in the presence
f the polymers during 96 h. Cells from the spleen are normally
esting cells and, when cultured in the absence of a mitogen, do
ot proliferate (Fig. 6C). In the presence of a mitogen, Con A,
he activated cells exhibited the highest values of [3H] thymidine
ptake. These values are used as the intended positive control
Fig. 6A). On the other hand, as shown in Fig. 6, while CpG
DN 1826 alone at concentrations of at least 6g/ml stimu-
ated splenocytes to proliferate, chitosan and alginate showed
o significant stimulation in both concentrations used. However,
ith higher concentrations of alginate, a large variability of theesults was observed (Fig. 6C).
The concomitant presence of the polymers chitosan or algi-
ate and the CpG or the Con A in the cell culture did not lead to
n increase of [3H] thymidine uptake by the cells (Fig. 6A and
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Fig. 5. Effect of the different compounds on the expression of the CD69 receptor on B cells. The compounds used were the immunostimulators, CpG ODN and Con
A and the biopolymers chitosan and alginate. Experiments with the combination between the biopolymers and the immunostimulators were also performed. The
filled histograms represent the group control (untreated) and the open histograms the stimulated (pretreated) group. The results are representative of two separate
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. Discussion
Stimulation of lymphocytes leads to upregulation of vari-
us cell surface markers at various stages of cellular activation:
D69 (very early), CD71 (early), CD25 (late), and HLA-Dr
very late) (Reddy et al., 2004). Lymphocytes have little basal
xpression of CD69, but following activation, CD69 is rapidly
xpressed (2–3 h) in all bone marrow-derived cells except ery-
hrocytes, as reviewed in (Testi et al., 1994; Sancho et al., 2005).
he precise role of CD69 in immunity has not been elucidated
wing to the absence of a known ligand and adequate in vivo
odels to study its physiological function (Sancho et al., 2005).
t was recently suggested that a transient activation-induced
D69 surface expression may be important for regulating T cell
rafficking (Feng et al., 2002). Moreover, CD69 might affect
he immune response during T-cell differentiation, involving
mmunoregulatory cytokines that include, but might not be lim-
ted to, TGF-, which controls T-cell differentiation. Recent
n vivo results indicate that this receptor acts as a regulatoryolecule, modulating the inflammatory response (Sancho et al.,
005). Based on several studies, it was reported (Morgan et al.,
999) that CD69 functions as a signal-generating receptor, pos-
ibly regulating the activity of the transcription factor AP-1 and
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pcorresponds to the entire data of one experiment and similar histograms were
ge of the positive B cells that express the CD69 antigen, obtained from three
L-2 gene expression through both AP-1 and NF-AT complexes.
he results presented by Morgan et al. (1999) also suggested that
D69 participates in a variety of processes within the overall
ctivation cascade.
Therefore, in vitro manipulation of early activation marker
D69 is an approach used in many laboratories to explore poten-
ial pathways of cellular activation and can be used to measure
he immunomodulatory effects of pharmaceutical agents and
accine antigens (Reddy et al., 2004).
Synthetic oligodeoxynucleotides (CpG ODNs) and bacterial
NA containing unmethylated CpG dinucleotides in the context
f particular base sequences (CpG motifs) are known to mediate
everal immune responses. In the present study it was shown that
pG ODN 1826 is a potent in vitro CD69 stimulator. Its presence
n a culture of mice splenocytes was shown to increase the size
nd granularity of B lymphocytes, which was accompanied by
strong expression of the CD69 receptor. Furthermore, a mild
ut statistically significant increase of the expression of CD69 in
-lymphocytes was also observed and was accompanied by high
ymphocyte proliferation. These conclusions, however, cannot
e generalized to include other CpG ODN, even if the concept of
he immunostimulatory CpG motif has become widely accepted.
ecently, it was demonstrated that not all DNA/ODN containing
pG motifs were equally stimulatory (Wang and Krieg, 2003)
nd CpG 1982 showed itself to be weaker than CpG 1826 in
romoting cell activation. CpG ODN 1826 at concentrations of
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Fig. 6. [3H] Thymidine incorporation, expressed in cpm (counts per minute),
by the proliferating splenocytes cultured with different compounds for 96 h. The
compounds experienced were the immunostimulators, CpG ODN and Con A and
two concentrations of the polymers chitosan and alginate. Conc1 = 0.312 mg/ml
and conc2 = 0.0125 mg/ml. Experiments with the combinations between the
biopolymers and the immunostimulators were also performed. Each bar is the
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equence specifically caused increased expression of CD69 on
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al and pathologic immune responses, is an important aspect
or a better understanding of the mechanisms involved (Wang
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o proliferate or to express CD69 antigen. On the other hand, an
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e potent CD69 activators, not only for B cells but in case of
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he literature with other compounds (Morgan et al., 1999), it is
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ctivation-induced because the observed CD69 expression was
ot followed by lymphocyte proliferation. On the other hand,
t is not known whether CD69 activation is always linked with
-lymphocyte proliferation and incomplete activation might be
ndicative of anergy (Sancho et al., 2005). Recently we have
eported (Borges et al., 2006) an increase in cell permeabil-
ty for propidium iodide, observed in lymphocytes treated with
olymers chitosan and alginate, and in the present study the
ame effect was confirmed (data not shown). Moreover, in an
n vitro study, chitosan was indicated as the cause of a slightly
eversible plasma membrane perturbation in Caco-2 cell mono-
ayers (Dodane et al., 1999). This feature is most likely an
ndication of cellular stress. Nonetheless, chitosan and alginate,
n the concentrations studied, did not show a suppressive effect
n the lymphocyte proliferation, induced by the mitogens, Con
or CpG nor had any cytotoxic effects on the cells. These
bservations are important and point out that the presence of
hese polymers, for instance in an antigen nanocarrier delivery
ystem, might not be able to induce a suppressive lymphocyte
roliferative effect, when internalized by a lymphoid organ. On
he contrary, and giving as example a recent study (Seferian and
artinez, 2000), where it was shown that chitosan based for-
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low molecular weight alginate, appropriate for pharmaceutical
pplications, like tissue engineering and vaccine delivery. Unex-
ectedly, lymphocytes upregulated CD69 expression when the
mmune cells were maintained in contact with the polymer. Sim-
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an upregulate CD69 expression on B cells and to a lesser extent
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. Conclusions
In this study lymphocytes underwent strong activation and
apid CD69 upregulation upon contact with the biopolymers
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uences for the initiation of an immune response. Moreover,
s these are in vitro studies employing mice spleen cells it
emains unknown whether the same effects would be observed
ith human cells or other peripheral lymphoid organs, such as
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